Search

Cancer biologist Nikolaus Schultz uses computational tools to study the diversity of genomic alterations underlying different cancer types.

… The Schultz lab focuses on identifying the genomic alterations that underlie different types of cancer. By applying existing and novel computational methods to large scale cancer genomics data sets, the lab aims to better understand the complex mechanisms at the gene and at the pathway level that drive

Physician-scientist Karlo Perica develops cell therapies to treat a wide variety of cancers, focusing on off-the-shelf approaches such as allogeneic CAR T cells and in vivo gene editing.

… The laboratory of Dr. Karlo Perica focuses on developing new Chimeric Antigen Receptor T cell and other cell therapies for cancer. We seek to make cell therapy more accessible and more effective by developing “off-the-shelf” approaches using allogeneic cell therapies and in vivo editing. Our research

Jonathan Coleman is a physician-scientist focused on translational research, cancer genomics, and patient-derived organoid models in the study of urologic malignancies. Ongoing work includes the development of local ablative therapies, their influence on the tumor microenvironment, and implications for therapy response.

… Our lab is focused on understanding the mechanism of disease recurrence, response to therapies and disease progression of upper tract urothelial cancer, a rare but aggressive disease. To interrogate molecular diversity of the disease, we employ genomics, transcriptomics, metabolomics and tumor immune

The Antonsecu lab focuses on translocation-associated sarcoma pathogenesis and generating in vitro models.

… An on-going focus of our work is the genomic investigation of pediatric and young adult unclassified mesenchymal tumors, with a special emphasis on detecting novel gene fusions drivers. By applying highly efficient RNAseq and FusionSeq pipelines for novel translocation discovery in tumors that lack known

Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.

… Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials

The Huangfu laboratory uses human pluripotent stem cells (hPSCs) as a powerful genetic model to interrogate the transcriptional and epigenetic mechanisms underlying cell fate decisions in development and disease.

… We apply both precision gene editing and large-scale CRISPR screening in human pluripotent stem cells (hPSCs) to explore mechanisms underlying human development. Specifically, we are interrogating the protein-coding regulators of pancreatic development and β cell function. The pathways that regulate

Molecular biologist Simon Powell investigates DNA replication and recombination, chromosome dynamics, and human genetics.

… The major theme of our work is how DNA repair processes are disrupted in human cancers and how this can be exploited therapeutically.   Join the Powell Lab! Simon N. Powell, MD, PhD Enid A. Haupt Chair in Radiation Oncology Professor PhD, MD, University of London Email [email protected] Laboratory phone

The Hite laboratory studies the mechanisms of ion and metabolite transport and the maintenance of genomic integrity.

… Our research group has two primary focuses. One part of the lab focuses on determining the mechanisms of intracellular ion and metabolite transport, while the second studies protein nucleic acid interactions that are critical for maintaining genomic integrity. We study these fundamental processes using

Derek Tan’s lab studies diversity-oriented synthesis and rational drug design of probes and lead compounds for chemical biology and drug discovery.

… The identification of small-molecule probes and therapeutic lead compounds to address novel biological targets is a significant current challenge in chemical biology and drug discovery. We are engaged in a two-pronged approach to this problem involving diversity-oriented synthesis and rational design

Alban Ordureau explores molecular signaling pathways that regulate cellular homeostasis, with a focus on the ubiquitin and autophagy systems.

… My group focuses on understanding cell signaling pathways primarily linked with the ubiquitin and autophagy systems and frequently altered in diseases, including neurodegenerative disease. To this end, we combine cell biological, genome engineering (CRISPR), and biochemical approaches to provide new